Study Background and Disease Burden
Atrial fibrillation (AF) is a prevalent arrhythmia in the elderly population, significantly increasing the risk of stroke and systemic embolic events. Vitamin K antagonists (VKAs), particularly warfarin, have long been the cornerstone of anticoagulant therapy for stroke prevention in AF. However, the advent of direct-acting oral anticoagulants (DOACs) introduced alternative options that offer advantages such as fewer dietary restrictions and drug interactions. Despite such benefits, the decision to switch frail and elderly AF patients—especially those with prior VKA exposure—to DOACs remains controversial, given concerns about bleeding risk, comorbidities, and pharmacodynamics sensitivity in this vulnerable group. Prior studies like the FRAIL-AF trial have yielded inconclusive results, compelling further evaluation using large clinical datasets.
